KROS

Keros Therapeutics is a clinical-stage biopharmaceutical company developing novel therapies for diseases caused by dysfunctional signaling of the transforming growth factor-beta (TGF-beta) family of proteins. The company's lead programs target hematologic and musculoskeletal disorders including myelodysplastic syndromes, pulmonary arterial hypertension, and fibrodysplasia ossificans progressiva. Keros leverages its expertise in TGF-beta biology to develop therapeutics addressing significant unmet medical needs.